Our Company
About Us
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Shingles, influenza, Coronavirus. YS Biopharma operates in China, Singapore, the United States, the United Arab Emirates and the Philippines with over 800 employees and led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry.
Management
Board of Directors
David (Hui) Shao
（PhD, MBA, CFA）
Director, President and Chief Executive Officer
Ajit Shetty
（PhD, MBA）
Chairperson of the Board of Directors of the Company
Viren Mehta
（PharmD, MBA）
Independent Director
Rachel Yu
Independent Director
Yuntao Cui
Independent Director
Pierson Yue Pan
Director
Chunyuan (Brenda) Wu
Director, Chief Financial Officer
Jin Wang
Independent Director
Henry Chen
Director
Haitao Zhao
Director
Scientific Advisor
Yunde Hou
（MD, PhD）
Yongxin Yu
Mann Fung
（M.D.）
Guang Gao
（Ph.D.）
